Congress quietly extends drug-price exemptions for pharmaceutical companies

What it does

This bill expands the orphan drug exemption from Medicare's drug price negotiation program. It allows drugs that were once designated as orphan drugs (for rare diseases affecting fewer than 200,000 people) to retain their exemption even after they are approved for broader uses, and clarifies that the time a drug spent under orphan status does not count toward the eligibility clock for price negotiation. This benefits pharmaceutical companies by extending the period during which they can charge higher prices without Medicare negotiation.

Why we flagged it

The bill's operative mechanism is to extend the orphan-drug exemption from Medicare price negotiation to drugs that were formerly orphan-designated but now treat multiple rare diseases. This is a direct carve-out that protects pharmaceutical pricing power and delays price negotiation.

What the text implies

• Drugs approved for multiple rare diseases (e.g., a cancer drug approved for three different rare cancers) can now claim orphan status for each indication separately, potentially extending exemption indefinitely as new rare-disease approvals accumulate.
• The bill does not require disclosure of how many patients actually use a drug for each rare-disease indication, creating potential for gaming: a drug with minimal rare-disease use but large non-rare-disease population could retain exemption based on small patient populations.
• Medicare's negotiation program, enacted in the Inflation Reduction Act, is designed to reduce drug costs for seniors; this bill carves out a category that may represent a growing share of specialty pharmaceuticals, undermining the program's cost-control intent.
• The definition of 'rare disease' is cross-referenced to the Federal Food, Drug, and Cosmetic Act § 526(a)(2), which defines it as affecting fewer than 200,000 people in the U.S.; a drug can be approved for multiple such conditions and retain exemption for each, compounding the carve-out.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people and Medicare beneficiaries face higher drug costs for longer periods. The bill extends pharmaceutical pricing power by allowing drugs to retain orphan-drug exemptions even after approval for multiple rare diseases, delaying Medicare's ability to negotiate prices and shifting costs to patients and the federal program.

Who stands to gain

• pharmaceutical companies with orphan-designated drugs
• specialty pharmaceutical manufacturers
• biotech firms developing rare-disease treatments

Named in the bill

Social Security Act § 1192(e), Drug Price Negotiation Program, Medicare, Federal Food, Drug, and Cosmetic Act § 526(a)(2), orphan drugs, rare diseases

Where it stands

18 cosponsors: 9 Democrats, 9 Republicans.

• Feb 4, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 4, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

39 lobbying clients named this bill on 55 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $36,978,726 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 99% of bills with at least one filing.

John Joyce, the sponsor, reported $1,473,437 in PAC receipts in the 2026 cycle. $8,500 of that came from 3 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• Astrazeneca Pharmaceuticals Lp — $2,350,000 on 2 filings
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing
• Novartis — $1,410,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.